News Article
Historic Turning Point in Myeloma
ODAC unanimously votes in favor of MRD testing
On April 12, 2024, the U.S. Food and Drug Administration (FDA) held the Oncologic Drugs Advisory Committee (ODAC) meeting to evaluate available data to support the use of minimal residual disease…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the August 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
Portland's "The Manual" features the article "Adventure for a cure: Myeloma survivors fighting back and advancing the cause," which discusses the International Myeloma Foundation's inaugural Iceland Cycling Expedition. It focuses…
News Article
Fox 26 (WTIV - Houston, TX) features IMF President and CEO Yelak Biru, as he prepares to leave for the International Myeloma Foundation's inaugural Iceland Cycling Expedition. The 3-day bike expedition includes patients, doctors,…
News Article
Watch the video and read the article from ABC 11 (WTVD in Durham, NC) about two cyclists who are taking part in the International Myeloma Foundation's inaugural Iceland Cycling Expedition, beginning August 29, 2024. These cyclists…
News Article
Read this article and watch a video with the International Myeloma Foundation's Chief Medical Officer Dr. Joseph Mikhael, as he explains the goals of the organization's inaugural Iceland Cycling Expedition. This event aims to raise…
News Article
The International Myeloma Foundation (IMF) Brings Back ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2024
LOS ANGELES, AUGUST 29, 2024 – With Blood Cancer Awareness Month coming up this September, the International Myeloma Foundation (IMF) is reviving…
News Article
The Brian D. Novis Grants Reception and Dinner took place on Saturday, August 17, at the Sheraton Universal Los Angeles in North Hollywood.
At the culmination of the Patient and Family Seminar (PFS) in Los Angeles, the IMF held its annual Brian D. Novis (BDN) Research Grant 2024…
Page
The IMF has created the Latin American Myeloma Network (LAMN) to conduct multinational trials, provide myeloma education to patients and providers, facilitate collaborative research, and deepen the myeloma expertise across the region of Latin America. It also serves to bring Latin American…
Event
On August 27th I will begin the 490-mile hike on the Camino de Santiago (the French Way) from Saint Jean Pied de Port in France to the Cathedral of Santiago de Compostela, Spain and will be raising donations for the International Myeloma Foundation. I anticipate the "Walk" will take 30 days. Over…
Page
Pedaling Through Iceland for a CauseThe Iceland Cycling Expedition brings together patients, care partners, myeloma experts, researchers, and supporters for an unforgettable cycling challenge across Iceland—all in support of the International Myeloma Foundation’s mission to prevent and cure myeloma…
Page
Say Hello to MyeloYour 24/7 AI Assistant for Myeloma Support!Ever have a question about myeloma pop up at 3 am, leaving you frustrated and searching for answers? Now you can get the answers you need, anytime. Say hello to Myelo®, your 24/7 generative-AI assistant, specifically designed to support…
News Article
NEW YORK CITY, August 15, 2024—The International Myeloma Foundation (IMF), in partnership with the National Medical Association (NMA), the W. Montague Cobb Institute, and the Student National Medical Association (SNMA), sent a delegation of twelve IMF Medical Student Scholars for…
News Article
According to an August 8, 2024, Sanofi press release, "Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant." This conclusion was based on new results from "the two-part, double-…
Videos
Dr. Joseph Mikhael provides a rapid overview of groundbreaking research in multiple myeloma, highlighted from ASCO and EHA conferences. Key studies focus on newly diagnosed and early relapsed patients, CAR T-cell therapies, bispecific antibodies, and immunotherapy sequencing. Key Points:…
Videos
Elranatamab (ELRA), a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody, has demonstrated efficacy and manageable safety in patients with relapsed or refractory multiple myeloma (RRMM). The MagnetisMM-32 study, a phase 3, open-label, multicenter, randomized trial, aims to compare…
News Article
In a U.S. Food and Drug Administration (FDA) press release on July 30, 2024, the FDA announced its approval of "daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) in combination with bortezomib, lenalidomide, and dexamethasone for induction and…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the July 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Event
As we celebrate the 25th anniversary of the Support Group Leaders Summit, we honor the profound impact of support. Each year, patients and care partners gather to share their stories, experiences, and knowledge. It is through the tireless dedication of our support group leaders that we’ve been…
News Article
“We’ve all been there and being part of the myeloma community allows us to share with others who are on a similar journey. Together, we are stronger.” – Jack Aiello
The International Myeloma Foundation honors Jack Aiello and his legacy of service to the myeloma community…
News Article
The International Myeloma Foundation Mourns the Passing of IMF Board Member and Support Group Leader Jack Aiello
STUDIO CITY, CA, July 16, 2024 — Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members,…
MagnetisMM-30, a Phase 1b Study of ELRA and IBER Combination in Relapsed Refractory Multiple Myeloma
Videos
Abstract Title:
MagnetisMM-30: Aphase1b,open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
Summary:
Dr. Alexander Lesokhin outlines a phase 1b clinical study called MagnetisMM-30,…
Videos
Abstract Title:
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)
Summary:
In…
Audio
An Interview with Myeloma Patient and Care Partner Jason and Chad
Their insights on dealing with a multiple myeloma diagnosis as a patient and care partner team
In this episode of "A Day in the Life," Jason Hendler and Chad Billmyer, a patient and care partner married couple, share…
Videos
Captured at the 15th Annual IMWG Summit
This video offers a glimpse into the International Myeloma Foundation's International Myeloma Working Group (IMWG), a collaboration of leading myeloma researchers and clinicians from around the world.
The IMWG plays a critical role in:
…
Videos
Stored and Harvested Stem Cells After CAR T-cell Therapy
In this week's Ask Dr. Durie, IMF Chief Scientific Officer and multiple myeloma expert Dr. Brian G.M. Durie addresses the question of whether stored and harvested stem cells can be utilized to enhance blood counts, especially following CAR…
Videos
Effects of Being Overweight on Risk of Multiple Myeloma
In this week's Ask Dr. Durie, IMF Chief Scientific Officer and multiple myeloma expert Dr. Brian G.M. Durie addresses a patient's concern about the association between obesity and the risk of myeloma.
Dr. Durie discusses…
News Article
The International Myeloma Foundation Thanks Dr. Brian G.M. Durie for 35 Years of Remarkable Leadership
Assembles Global Dream Team and Establishes Scientific Advisory Board to Accelerate Myeloma Research
STUDIO CITY, CA, July 3, 2024—The International Myeloma Foundation (IMF) today…
Page
The IMF has culled the best information from external resources and peer organizations to help guide you through your caregiving journey: The Cancer Caregiver Podcast "is for the…
Page
The picture of medical coverage for a patient varies on a case-by-case basis, and navigating the cost of care often falls in the hands of care partners. While some patients have private insurance, others are on state-administered plans. Some may be on…
Page
Maybe you are a parent with young children or teens, or a spouse or partner who must share your myeloma diagnosis with your loved one. Talking about cancer is never easy, but it is always necessary. The following links provide options on how to share your diagnosis with your loved ones, as well as…
Page
Maybe you need help with household chores or cooking. Perhaps you need a better way to track your loved one's medical records. The following resources will help you on your care partner journey:An IMF…
Page
Caregivers, or care partners, often feel overly taxed by their duties. Remember, once you board a plane, you are always advised to put on your oxygen mask first before assisting your loved ones. The same rule is true for care partners. Listed here are some resources…
Audio
Hip. Hope. Hooray! Men Talkin' Health
Myeloma survivor, advocate, and Founder of the Health, Hope, & Hip-Hop Foundation, Oya Gilbert, creates a dynamic space for men to share their health stories, struggles, and successes. Each episode features real conversations with men from all walks of…
Videos
Abstract Title:
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma: Interim Analysis of the GMMG-HD7 Trial
Summary:
The GMMG-HD7 trial evaluated the efficacy of adding isatuximab (Isa) to…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the June 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Abstract Title:
A Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 FASTCAR-T (GC012F) as First-Line Therapy for Transplanteligible Newly Diagnosed High-Risk Multiple Myeloma
Summary:
This abstract presents the results of a phase I study…
Videos
Abstract Title:
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma: Interim Analysis of the GMMG-HD7 Trial
Summary:
The GMMG-HD7 trial evaluated the efficacy of adding isatuximab (Isa) to…
Videos
Abstract Title:
Class comparison of BCMA-directed therapies in relapsed multiple myeloma
Summary:
This retrospective study evaluated the efficacy of BCMA-directed therapies in relapsed multiple…
Videos
Abstract Title:
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of…
Videos
Abstract Title:
Efficacy, Safety, and Determination of RP2D of ABBV-383, a BCMA Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Summary:
The phase 1 trial of ABBV-383, a BCMA bispecific antibody, in patients with…
Page
Myeloma and myeloma treatment can lead to changes that affect the eyes (ocular toxicity) ranging from how well a person can see (visual acuity) to tissue damage (i.e. corneal, retinal). Often, these changes are temporary, may continue until treatment is received, or may only occur while on a…
Videos
Abstract Title:
Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Depth and Durability of Response at 14-Month Median Follow-Up
Summary:
The study evaluated the efficacy and safety of linvoseltamab, a B-cell…
Videos
Effects of FDA Approval of MRD testing for Myeloma on Patients and Drug Development
In this week's Ask Dr. Durie, IMF Chief Scientific Officer and multiple myeloma expert Dr. Brian G.M. Durie discusses the recent FDA approval of MRD (minimal residual disease) testing as an early endpoint for…
Page
Cytokine release syndrome (CRS) is a condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. Cytokines are small proteins that play a crucial role in regulating immune responses and inflammation. In normal…
Videos
Abstract Title:
Idecabtagene Vicleucel (ide-cel) in Patients (Pts) with Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Frontline (1L) Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2b
Summary:
KarMMa-2 is a multicohort, phase…